Postpartum dysgalactia syndrome (PPDS) and locomotory disorders are common health problems in sows. Previous research suggests that they can cause substantial losses, reduce sow welfare, and result in premature removal of the sow from the herd. However, economic consequences of PPDS and locomotory disorders have not been investigated thoroughly. The goal of this study was to examine economic losses caused by PPDS and locomotory disorders and their impacts on sow longevity. A stochastic dynamic programming model, which maximizes return on sow space unit and assesses sow replacement under several scenarios, was developed. The state variables were litter size, parity number, and sow’s health status. The model describes changes in the production parameters such as the number of piglets born and piglet mortality. Herd data originating from commercial sow herds and from a research farm were used to parameterize the model. Sow longevity, health, and economic results are related to each other. Eliminating the risk of PPDS from the model increased the value of sow space unit by €279 when compared to the baseline scenario. Eliminating the risk of locomotory disorders increased value by €110. Results suggest that these estimates correspond to about €29.1 and €11.5 in economic costs per housed sow during her lifetime. The estimated magnitude of losses was €300–€470 per affected sow for PPDS and €290–€330 per affected sow for locomotory disorders. However, realistically speaking, not all of these costs are avoidable. Due to premature replacement associated with these two disorders, the average number of litters that the sow would deliver during her lifetime is decreased by about 0.1–0.4 litters depending on the scenario. We also observed that the optimal lifetime of a sow is not a fixed number, but it depends on her productivity level as well as health status. In general, a healthy sow could stay in the herd until she has produced 6–10 litters. Research is needed to understand the structures and interactions underlying health impairments, performance, replacement policies, and farm economics, and to provide pork producers with management recommendations.

No abstract

Background: By definition bronchiectasis (BE) means destructed structure of normal bronchus as a consequence of frequent bacterial infections and inflammation. In many senses, BE is a neglected orphan disease. A recent pan-European registry study, EMBARC, has been set up in order to better understand its pathophysiology, better phenotype patients, and to individualize their management. Aim: To examine the aetiology and co-morbidity of BE in the capital area in Finland. Methods: Two hundred five patients with BE diagnosis and follow up visits between 2016 and 2017 in Helsinki University Hospital were invited to participate in the study. Baseline demographics, lung functions, imaging, microbiological, and therapeutic data, together with co-morbidities were entered into EMBARC database. Clinical characteristics, aetiologic factors, co-morbidities, and risk factors for extensive BE were explored. Results: To the study included 95 adult patients and seventy nine percent of the BE patients were women. The mean age was 69 years (SD ± 13). Asthma was a comorbid condition in 68% of the patients but in 26% it was estimated to be the cause of BE. Asthma was aetiological factor for BE if it had been diagnosed earlier than BE. As 41% BE were idiopathic, in 11% the disorder was postinfectious and others were associated to rheumatic disease, Alpha-1-antitrypsin deficiency, IgG deficiency and Kartagener syndrome. The most common co-morbidities in addition to asthma were cardiovascular disease (30%), gastroesophageal reflux disease (26%), overweight (22%), diabetes (16%), inactive neoplasia (15%), and immunodeficiency (12%). Extensive BE was found in 68% of BE patients in whom four or more lobes were affected. Risk factors for extensive BE were asthma (OR 2.7), asthma as aetiology for BE (OR 4.3), and rhinosinusitis (OR 3.1). Conclusions: Asthma was associated to BE in 68% and it was estimated as aetiology in every fourth patient. However, retrospectively, it is difficult to exclude asthma as a background cause in patients with asthma-like symptoms and respiratory infections. We propose asthma as an aetiology factor for BE if it is diagnosed earlier than BE. Asthma and rhinosinusitis were predictive for extensive BE.

In vitro cancer drug testing carries a low predictive value. We developed the human leiomyoma–derived matrix “Myogel” to better mimic the human tumor microenvironment (TME). We hypothesized that Myogel could provide an appropriate microenvironment for cancer cells, thereby allowing more in vivo–relevant drug testing. We screened 19 anticancer compounds, targeting the epidermal growth factor receptor (EGFR), MEK, and PI3K/mTOR on 12 head and neck squamous cell carcinoma (HNSCC) cell lines cultured on plastic, mouse sarcoma–derived Matrigel (MSDM), and Myogel. We applied a high-throughput drug screening assay under five different culturing conditions: cells in two-dimensional (2D) plastic wells and on top or embedded in Matrigel or Myogel. We then compared the efficacy of the anticancer compounds to the response rates of 19 HNSCC monotherapy clinical trials. Cancer cells on top of Myogel responded less to EGFR and MEK inhibitors compared to cells cultured on plastic or Matrigel. However, we found a similar response to the PI3K/mTOR inhibitors under all culturing conditions. Cells grown on Myogel more closely resembled the response rates reported in EGFR-inhibitor monotherapy clinical trials. Our findings suggest that a human tumor matrix improves the predictability of in vitro anticancer drug testing compared to current 2D and MSDM methods.